NEO vs. APDN, ULS, ENSG, VKTX, JAZZ, BPMC, MASI, EXEL, ACHC, and RVMD
Should you be buying NeoGenomics stock or one of its competitors? The main competitors of NeoGenomics include Applied DNA Sciences (APDN), UL Solutions (ULS), The Ensign Group (ENSG), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Masimo (MASI), Exelixis (EXEL), Acadia Healthcare (ACHC), and Revolution Medicines (RVMD).
Applied DNA Sciences (NASDAQ:APDN) and NeoGenomics (NASDAQ:NEO) are both small-cap industrial products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Applied DNA Sciences has higher earnings, but lower revenue than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Applied DNA Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Applied DNA Sciences had 3 more articles in the media than NeoGenomics. MarketBeat recorded 7 mentions for Applied DNA Sciences and 4 mentions for NeoGenomics. Applied DNA Sciences' average media sentiment score of 0.81 beat NeoGenomics' score of 0.39 indicating that NeoGenomics is being referred to more favorably in the news media.
22.2% of Applied DNA Sciences shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 10.3% of Applied DNA Sciences shares are held by company insiders. Comparatively, 1.3% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Applied DNA Sciences presently has a consensus price target of $7.00, suggesting a potential upside of 1,074.89%. NeoGenomics has a consensus price target of $19.78, suggesting a potential upside of 44.26%. Given NeoGenomics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Applied DNA Sciences is more favorable than NeoGenomics.
NeoGenomics received 204 more outperform votes than Applied DNA Sciences when rated by MarketBeat users. Likewise, 70.66% of users gave NeoGenomics an outperform vote while only 58.99% of users gave Applied DNA Sciences an outperform vote.
Applied DNA Sciences has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
NeoGenomics has a net margin of -13.79% compared to NeoGenomics' net margin of -222.33%. Applied DNA Sciences' return on equity of -3.54% beat NeoGenomics' return on equity.
Summary
NeoGenomics beats Applied DNA Sciences on 12 of the 18 factors compared between the two stocks.
Get NeoGenomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeoGenomics Competitors List
Related Companies and Tools
